CytomX Therapeutics, Inc. (NASDAQ: CTMX)

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet needs in cancer. The company leverages its PROBODY technology platform to create conditionally activated, masked biologics designed to selectively target tumors while minimizing toxicity in healthy tissues. Its core activities involve research, development, and clinical testing of therapeutic candidates across multiple modalities, including antibody-drug conjugates, T-cell engagers, and cytokines.

CytomX generates revenue primarily through strategic collaborations with major biopharmaceutical companies, which include upfront payments, milestone payments, and potential future royalties. The company has entered into alliances with Amgen, Astellas, Bristol Myers Squibb, Moderna, and Regeneron to advance its pipeline of PROBODY therapeutics. These partnerships provide funding for preclinical and clinical development, as well as access to additional resources and expertise. Revenue is derived from the achievement of development, regulatory, and commercial milestones under these agreements.

The company operates through the following segments:

• PROBODY Antibody-Drug Conjugates: This segment focuses on the development of conditionally activated ADCs such as Varseta-M, which targets EpCAM and is armed with a topoisomerase-1 inhibitor payload. Varseta-M is designed to optimize the therapeutic index for EpCAM-expressing cancers, including colorectal cancer. The payload-antibody linker is engineered to drive bystander killing of neighboring tumor cells.

• PROBODY Cytokines: This segment includes CX-801, a dually-masked, conditionally activated version of interferon alpha-2b designed to be preferentially active in the tumor microenvironment. CX-801 leverages a peptide mask and an Fc steric mask to limit systemic activity and extend half-life. The program is currently in Phase 1 development for advanced melanoma, both as monotherapy and in combination with KEYTRUDA®.

• PROBODY T-Cell Engagers: This segment encompasses preclinical programs such as CX-908, a dually-masked PROBODY TCE targeting CDH3 and CD3, developed in collaboration with Amgen. The segment also includes ongoing TCE efforts with Bristol Myers Squibb and Regeneron. These therapies are designed to widen the therapeutic window by reducing cytokine release and improving tolerability compared to unmasked counterparts.

CytomX holds a pioneering position in the field of conditionally activated biologics through its PROBODY technology platform, which enables selective tumor targeting and improved therapeutic index. The company faces competition from entities such as AbbVie, Amgen, Bristol Myers Squibb, Merck, Roche, and Takeda in the ADC, TCE, and immunotherapy spaces. Its competitive advantages stem from over 15 years of PROBODY platform expertise, a strong intellectual property portfolio with at least 245 granted patents and 300 pending applications, and deep knowledge of tumor-associated proteases. The versatility of the platform across modalities allows CytomX to address targets that are limited by toxicity in healthy tissues, such as EpCAM and interferon alpha-2b.

CytomX serves patients with advanced solid tumors, particularly those with colorectal cancer and melanoma, who have exhausted standard treatment options. The company's clinical programs focus on late-line metastatic colorectal cancer and advanced melanoma, where treatment alternatives are limited. Its therapeutic candidates are intended for use in combination with existing therapies such as bevacizumab and KEYTRUDA® to improve outcomes in difficult-to-treat populations.